Inovio and Akeso Partner on Novel Glioblastoma Therapy, Dosing Expected H2 2026
INO sits 35% above its 52-week low of $1.3.
Summary
Inovio Pharmaceuticals announced a clinical collaboration with Akeso to develop a novel combination therapy for Glioblastoma (GBM), a severe form of brain cancer. This partnership aims to advance a new treatment approach, with initial patient dosing anticipated in the second half of 2026. For Inovio, a small-cap biotech, this collaboration represents a significant expansion of its clinical pipeline and a strategic move into a high-unmet-need oncology area. The initiation of a new clinical trial, even in early stages, provides a potential long-term value driver. Investors will be watching for updates on trial enrollment and early safety/efficacy data.
At the time of this announcement, INO was trading at $1.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $115.4M. The 52-week trading range was $1.30 to $2.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.